Objective: To evaluate the clinical efficacy of Anpa Ningshen Decoction in treating Parkinson's disease (PD) patients with insomnia of the liver-kidney yin deficiency type. Methods: Sixty PD patients with insomnia of the liver-kidney yin deficiency type were randomly divided into a control group and an observation group, with 30 patients in each group. The control group was treated with eszopiclone, while the observation group received Anpa Ningshen Decoction in addition to eszopiclone. The treatment course for both groups was 4 weeks. The following parameters were compared before and after treatment between the two groups: polysomnography (PSG) parameters [including sleep latency (SL), number of awakenings (NA), wake after sleep onset (WASO), total sleep time (TST), sleep efficiency (SE), percentage of stage N1 sleep, percentage of stage N2 sleep, percentage of stage N3 sleep (slow-wave sleep), and percentage of REM sleep], subjective sleep quality [assessed using the Pittsburgh Sleep Quality Index (PSQI) and the Parkinson's Disease Sleep Scale (PDSS)], and changes in Traditional Chinese Medicine (TCM) syndrome scores. Results: After treatment, PSG parameters improved in both groups compared to before treatment, manifested as increased TST, decreased SL and WASO, reduced NA, improved SE, decreased percentages of N1 and N2 sleep, and increased percentages of N3 and REM sleep (P < 0.01). After treatment, the scores of all scales and TCM syndrome scores also improved in both groups compared to before treatment, manifested as decreased PSQI scores, increased PDSS scores, and reduced TCM syndrome scores (P < 0.01). The degree of improvement in all the above indicators was significantly greater in the observation group than in the control group (P < 0.05 or P < 0.01). Conclusion:Anpa Ningshen Decoction combined with eszopiclone can significantly improve sleep quality, enhance sleep continuity and sleep structure integrity in PD patients with insomnia, and its efficacy is superior to eszopiclone alone.